News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Baxa Corporation Bolsters Patient Safety With ExactaMix(R) Compounder Software Upgrade


11/2/2011 12:43:08 PM

ENGLEWOOD, Colo., Nov. 2, 2011 /PRNewswire/ -- Baxa Corporation, a leading provider of medical devices and systems that automate pharmacy operations, has released a software upgrade for its ExactaMix® Automated Compounding Devices (ACD). The new functionality includes 14 updates that provide Directors of Pharmacy with enhanced patient safety measures and features.

Hospital pharmacies worldwide use ExactaMix 2400 (EM2400) and ExactaMix 1200 (EM1200) to compound large- and small-volume parenteral doses. Baxa Corporation leads the ACD category with 65% of the global US market share, according to a recent poll in Pharmacy Purchasing & Productsmagazine.

Improved Efficiency, Added Safety Set Industry Standard

ExactaMix ACDs automatically compound multi-ingredient sterile doses, minimizing the risk of measurement errors, wrong drug selection, touch contamination and patient infection in the preparation of solutions for total parenteral nutrition (TPN), cardioplegia, dialysis and epidural delivery.

To facilitate the upgrade, current ExactaMix customers will have one-on-one live installation support. The ExactaMix software release includes the following key features for EM2400 and EM1200 users:

  • Water is now the default calibration ingredient for the US market. The calibration source was redefined to allow multiple water calibration products.
  • The current patient formula is unloaded when the user exits the compounder screen, reducing the potential for the user to pump a wrong formula into the bag.
  • New priming process improves the purging of air bubbles in the inlets prior to pumping, enhancing the user prime process.
  • Integration with DoseEdge® Pharmacy Workflow Manager enables pharmacies to export MixCheck Report data for use with DoseEdge TPN.

State-of-the-art Baxa compounding technology delivers final bag accuracies within + 3% with barcode ingredient verification, and pumps a typical three-liter nutrition bag in approximately 3.5 minutes nearly two times faster than the industry average. ExactaMix provides volumetric delivery and gravimetric check with the ability to mix both micro and macro ingredients as low as 0.2 mL. ExactaMix compounding efficiency enables pharmacy professionals to focus on patient care with the confidence that safety, regulatory compliance and preparation accuracy goals are met.

"The first company to offer automated compounding of both micro and macro ingredients in a single device, Baxa ACDs now serve over 20,000 patients daily across the globe," said Mark Miller, Product Manager at Baxa Corporation. "In fact, 2012 marks the 10-year anniversary of doses compounded safely on the ExactaMix 2400 Compounder."

Baxa Corporation reliably and consistently enables pharmacists in more than 3,000 hospitals worldwide to safely prepare and administer intravenous therapies. To learn more about the ExactaMix line of ACDs, visit www.baxa.com/exactamix/.

For additional information on Baxa IV automation, to request a product brochure or download a free, educational white paper, visit www.baxa.com/ivroom/, call 800.567.2292 or email info@baxa.com.

About Baxa Corporation

Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for medication handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging and administration of medications. Key products used worldwide in hospitals and healthcare facilities include: the Abacus® Order Entry and Calculation Software, the DoseEdge® Pharmacy Workflow Manager, ExactaMed® Oral Syringes, ExactaMix® Automated Compounding Devices, InFuse and MicroFuse® Syringe Infusers, Repeater Pharmacy Pumps, NeoThrive® Enteral Syringes, the PadLock® Set Saver and the RapidFill and IntelliFill® i.v. Automated Syringe Fillers. Privately held, Baxa Corporation has subsidiaries and sales offices in Florida, Canada and the United Kingdom; direct representation in Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, The Netherlands and Switzerland; and distribution partners worldwide. Further information is available at www.baxa.com.

Contact:
Marian Robinson, Vice President, Marketing
Baxa Corporation: 800.567.2292 ext. 2157 or 303.617.2157
Email: marian.robinson@baxa.com

Perrin McCormick
HB: 781-893-0053
Email: baxa@hbagency.com

SOURCE Baxa Corporation


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES